A Phase 1, Open Label, Multi-center Study to Assess the Safety, Pharmacokinetics and Effectiveness of AGS-16C3F Monotherapy in Subjects With Renal Cell Carcinoma (RCC) of Clear Cell or Papillary Histology
Phase of Trial: Phase I
Latest Information Update: 30 May 2018
Price : $35 *
At a glance
- Drugs AGS 16C3F (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions
- Sponsors Agensys
- 30 May 2018 Results of two phase1 trial (NCT01114230 and NCT01672775), were published in the Clinical cancer research: an official journal of the American Association for Cancer Research.
- 13 Apr 2017 Status changed from active, no longer recruiting to completed.
- 05 Feb 2016 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016, according to ClinicalTrials.gov record.